CRISPR–Cas9 hits its target in amyloidosis
Nature Medicine explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron’s gene-editing treatment, which reduced levels of transthyretin in patients. Nature Medicine explores the latest translational and clinical research news, with an analysis of Inte...
Gespeichert in:
| Veröffentlicht in: | Nature medicine 2022-12, Vol.28 (12), p.2438-2438 |
|---|---|
| 1. Verfasser: | |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2438 |
|---|---|
| container_issue | 12 |
| container_start_page | 2438 |
| container_title | Nature medicine |
| container_volume | 28 |
| creator | Carvalho, Thiago |
| description | Nature Medicine
explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron’s gene-editing treatment, which reduced levels of transthyretin in patients.
Nature Medicine explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron’s gene-editing treatment, which reduced levels of transthyretin in patients.
Image credit: Denis Pobytov / DigitalVision Vectors / Getty |
| doi_str_mv | 10.1038/d41591-022-00101-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2724584266</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2759128502</sourcerecordid><originalsourceid>FETCH-LOGICAL-c403t-17e1f00944d30e7484b5e75ac9f6fda318183ae40dd29d114e746bb7eb44f7ff3</originalsourceid><addsrcrecordid>eNqFkE9LwzAchoMobk6_gAcpePFg9Zd_TXqU4p_BQJkK3kLaprOjXWfSHnbzO_gN_SRmdip40ENIIM_vfZMHoUMMZxioPM8Z5jEOgZAQAAMO2RYaYs6iEAt42vZnEDKUMY8GaM-5OQBQ4PEuGtCIEEYiPkSnyXR8fzd9f31LtIuD57J1wXq12s5MG5SLQNerqinzxpVuH-0UunLmYLOP0OPV5UNyE05ur8fJxSTMGNDWtxtcAMSM5RSMYJKl3Aius7iIilxTLLGk2jDIcxLnGDPPRGkqTMpYIYqCjtBJn7u0zUtnXKvq0mWmqvTCNJ1TRBDGpf9A5NHjX-i86ezCv85TPF6XC_4fhYnkQDxFeiqzjXPWFGppy1rblcKg1sZVb1x54-rTuGJ-6GgT3aW1yb9HvhR7gPaA81eLmbE_3X_EfgDE_4ih</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2759128502</pqid></control><display><type>article</type><title>CRISPR–Cas9 hits its target in amyloidosis</title><source>MEDLINE</source><source>Nature</source><source>Alma/SFX Local Collection</source><creator>Carvalho, Thiago</creator><creatorcontrib>Carvalho, Thiago</creatorcontrib><description>Nature Medicine
explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron’s gene-editing treatment, which reduced levels of transthyretin in patients.
Nature Medicine explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron’s gene-editing treatment, which reduced levels of transthyretin in patients.
Image credit: Denis Pobytov / DigitalVision Vectors / Getty</description><identifier>ISSN: 1078-8956</identifier><identifier>EISSN: 1546-170X</identifier><identifier>DOI: 10.1038/d41591-022-00101-4</identifier><identifier>PMID: 36224265</identifier><language>eng</language><publisher>London: Nature Publishing Group UK</publisher><subject>Amyloidosis ; Amyloidosis - genetics ; Biomedicine ; Cancer Research ; CRISPR ; CRISPR-Associated Protein 9 - metabolism ; CRISPR-Cas Systems - genetics ; Editing ; Gene Editing ; Genetic modification ; Humans ; Infectious Diseases ; Metabolic Diseases ; Molecular Medicine ; Neurosciences ; News ; Patients ; Translation ; Transthyretin</subject><ispartof>Nature medicine, 2022-12, Vol.28 (12), p.2438-2438</ispartof><rights>Springer Nature Limited 2022</rights><rights>Springer Nature Limited 2022.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c403t-17e1f00944d30e7484b5e75ac9f6fda318183ae40dd29d114e746bb7eb44f7ff3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>315,781,785,27929,27930</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36224265$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Carvalho, Thiago</creatorcontrib><title>CRISPR–Cas9 hits its target in amyloidosis</title><title>Nature medicine</title><addtitle>Nat Med</addtitle><addtitle>Nat Med</addtitle><description>Nature Medicine
explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron’s gene-editing treatment, which reduced levels of transthyretin in patients.
Nature Medicine explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron’s gene-editing treatment, which reduced levels of transthyretin in patients.
Image credit: Denis Pobytov / DigitalVision Vectors / Getty</description><subject>Amyloidosis</subject><subject>Amyloidosis - genetics</subject><subject>Biomedicine</subject><subject>Cancer Research</subject><subject>CRISPR</subject><subject>CRISPR-Associated Protein 9 - metabolism</subject><subject>CRISPR-Cas Systems - genetics</subject><subject>Editing</subject><subject>Gene Editing</subject><subject>Genetic modification</subject><subject>Humans</subject><subject>Infectious Diseases</subject><subject>Metabolic Diseases</subject><subject>Molecular Medicine</subject><subject>Neurosciences</subject><subject>News</subject><subject>Patients</subject><subject>Translation</subject><subject>Transthyretin</subject><issn>1078-8956</issn><issn>1546-170X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqFkE9LwzAchoMobk6_gAcpePFg9Zd_TXqU4p_BQJkK3kLaprOjXWfSHnbzO_gN_SRmdip40ENIIM_vfZMHoUMMZxioPM8Z5jEOgZAQAAMO2RYaYs6iEAt42vZnEDKUMY8GaM-5OQBQ4PEuGtCIEEYiPkSnyXR8fzd9f31LtIuD57J1wXq12s5MG5SLQNerqinzxpVuH-0UunLmYLOP0OPV5UNyE05ur8fJxSTMGNDWtxtcAMSM5RSMYJKl3Aius7iIilxTLLGk2jDIcxLnGDPPRGkqTMpYIYqCjtBJn7u0zUtnXKvq0mWmqvTCNJ1TRBDGpf9A5NHjX-i86ezCv85TPF6XC_4fhYnkQDxFeiqzjXPWFGppy1rblcKg1sZVb1x54-rTuGJ-6GgT3aW1yb9HvhR7gPaA81eLmbE_3X_EfgDE_4ih</recordid><startdate>20221201</startdate><enddate>20221201</enddate><creator>Carvalho, Thiago</creator><general>Nature Publishing Group UK</general><general>Nature Publishing Group</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7QG</scope><scope>7QL</scope><scope>7QP</scope><scope>7QR</scope><scope>7T5</scope><scope>7TK</scope><scope>7TM</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88A</scope><scope>88E</scope><scope>88I</scope><scope>8AO</scope><scope>8FD</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9.</scope><scope>LK8</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>M2P</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>P64</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>RC3</scope><scope>7X8</scope></search><sort><creationdate>20221201</creationdate><title>CRISPR–Cas9 hits its target in amyloidosis</title><author>Carvalho, Thiago</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c403t-17e1f00944d30e7484b5e75ac9f6fda318183ae40dd29d114e746bb7eb44f7ff3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Amyloidosis</topic><topic>Amyloidosis - genetics</topic><topic>Biomedicine</topic><topic>Cancer Research</topic><topic>CRISPR</topic><topic>CRISPR-Associated Protein 9 - metabolism</topic><topic>CRISPR-Cas Systems - genetics</topic><topic>Editing</topic><topic>Gene Editing</topic><topic>Genetic modification</topic><topic>Humans</topic><topic>Infectious Diseases</topic><topic>Metabolic Diseases</topic><topic>Molecular Medicine</topic><topic>Neurosciences</topic><topic>News</topic><topic>Patients</topic><topic>Translation</topic><topic>Transthyretin</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Carvalho, Thiago</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Animal Behavior Abstracts</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Chemoreception Abstracts</collection><collection>Immunology Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>Nucleic Acids Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Biology Database (Alumni Edition)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Science Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Technology Research Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>ProQuest Biological Science Collection</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Science Database</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>Genetics Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Nature medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Carvalho, Thiago</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CRISPR–Cas9 hits its target in amyloidosis</atitle><jtitle>Nature medicine</jtitle><stitle>Nat Med</stitle><addtitle>Nat Med</addtitle><date>2022-12-01</date><risdate>2022</risdate><volume>28</volume><issue>12</issue><spage>2438</spage><epage>2438</epage><pages>2438-2438</pages><issn>1078-8956</issn><eissn>1546-170X</eissn><abstract>Nature Medicine
explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron’s gene-editing treatment, which reduced levels of transthyretin in patients.
Nature Medicine explores the latest translational and clinical research news, with an analysis of Intellia and Regeneron’s gene-editing treatment, which reduced levels of transthyretin in patients.
Image credit: Denis Pobytov / DigitalVision Vectors / Getty</abstract><cop>London</cop><pub>Nature Publishing Group UK</pub><pmid>36224265</pmid><doi>10.1038/d41591-022-00101-4</doi><tpages>1</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1078-8956 |
| ispartof | Nature medicine, 2022-12, Vol.28 (12), p.2438-2438 |
| issn | 1078-8956 1546-170X |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2724584266 |
| source | MEDLINE; Nature; Alma/SFX Local Collection |
| subjects | Amyloidosis Amyloidosis - genetics Biomedicine Cancer Research CRISPR CRISPR-Associated Protein 9 - metabolism CRISPR-Cas Systems - genetics Editing Gene Editing Genetic modification Humans Infectious Diseases Metabolic Diseases Molecular Medicine Neurosciences News Patients Translation Transthyretin |
| title | CRISPR–Cas9 hits its target in amyloidosis |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T16%3A37%3A56IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CRISPR%E2%80%93Cas9%20hits%20its%20target%20in%20amyloidosis&rft.jtitle=Nature%20medicine&rft.au=Carvalho,%20Thiago&rft.date=2022-12-01&rft.volume=28&rft.issue=12&rft.spage=2438&rft.epage=2438&rft.pages=2438-2438&rft.issn=1078-8956&rft.eissn=1546-170X&rft_id=info:doi/10.1038/d41591-022-00101-4&rft_dat=%3Cproquest_cross%3E2759128502%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2759128502&rft_id=info:pmid/36224265&rfr_iscdi=true |